mRNA合成原料市場規模、佔有率和成長分析：按原料類型、修飾核苷、應用、最終用戶、通路和地區分類－2026-2033年產業預測

2024 年全球 mRNA 合成原料市場價值為 25.2 億美元，預計到 2025 年將成長至 28.9 億美元，到 2033 年將成長至 88.5 億美元，在預測期（2026-2033 年）內複合年成長率為 14.82%。

mRNA合成原料市場正受到mRNA疫苗和療法需求激增、生物技術研發投入增加以及相關產品臨床管線擴展的推動。隨著mRNA候選藥物從研發階段邁向臨床階段，生物製造技術亟需加速發展，並更加重視個人化醫療。此外，對適用於大規模生產的GMP級原料的需求不斷成長，迫使生物技術公司確保獲得符合監管規定的原料。這有助於擴大關鍵成分的產能，緩解供應瓶頸，並提高生產效率。然而，儘管新一代疫苗和療法前景廣闊，但高昂的生產成本、嚴格的監管以及供應鏈限制等挑戰可能會阻礙市場成長。

全球mRNA合成原料市場按原料類型、應用、最終用戶、分銷管道和地區進行細分。依原料類型分類，市場分為核苷三磷酸（NTP）、修飾核苷（m1Ψ、假尿苷）、帽類似物（ARCA、CleanCap）、poly(A)尾加成試劑和質體DNA模板。按應用分類，市場分為疫苗生產、治療和研究。依最終用戶分類，市場分為mRNA疫苗生產商、製藥和生物技術公司以及合約研發生產機構（CDMO）。依分銷通路分類，市場分為B2B直銷及分銷商。依地區分類，市場分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球mRNA合成原料市場的成長要素

隨著生物製藥公司加強開發平臺並探索更廣泛的應用，對基於mRNA的藥物和治療方法的需求日益成長，顯著推高了對原料的需求。對高品質核苷酸、酵素和特殊試劑的需求激增，促使製造商從概念階段邁向臨床試驗，最終推向市場。因此，供應商被鼓勵擴大營運規模，並為這些關鍵原料開發創新解決方案。該行業的持續成長正在吸引投資進入價值鏈，並促進支持供應商產能擴張的供應鏈網路的發展。反過來，這將加速新型mRNA的應用，並改善市場准入。

全球mRNA合成原料市場的限制因素

全球mRNA合成原料市場面臨供應鏈固有複雜性所帶來的許多限制因素，影響了市場規模與滲透率。關鍵細分領域原料供應商數量有限，導致供應穩定性和可靠性有隱憂。溫度敏感型原料的運輸進一步加劇了物流複雜性，可能導致延誤和品質問題，促使企業採取保守的庫存管理策略。這種關鍵原料供應的不確定性阻礙了生產流程的快速擴張，提高了新進業者和創新配方的進入門檻。因此，買家往往更傾向於選擇成熟可靠的供應商，導致新興製造商和新產品進入市場的速度較為緩慢。

mRNA合成原料市場的全球趨勢

受治療平台多元化的推動，全球mRNA合成原料市場正經歷顯著的發展趨勢。特別是，mRNA技術在腫瘤學、罕見疾病和再生醫學領域的應用不斷拓展，帶動了對各類高品質原料需求的成長。因此，試劑供應商如今提供專門設計的核苷酸、修飾的帽結構和專有賦形劑，以滿足特定的治療需求。這種發展趨勢正在加強試劑生產商和生物技術公司之間的合作，以製定這些原料的客製化規格，凸顯了客製化解決方案在滿足mRNA合成市場多樣化需求方面的重要性。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球mRNA合成原料市場規模：依原料類型分類

• 核苷三磷酸（NTP）
• 修飾核苷（m1Ψ，假尿苷）
• 電容模擬（ARCA、CleanCap）
• Poly-A尾部添加試劑
• 質體DNA模板

全球mRNA合成原料市場規模：依應用領域分類

• 疫苗生產
• 治療
• 調查

全球mRNA合成原料市場規模：依最終用戶分類

• 埃爾納爾疫苗生產商
• 製藥和生物技術公司
• CDMO

全球mRNA合成原料市場規模：依分銷管道分類

• 直接B2B
• 銷售代理

全球mRNA合成原料市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Thermo Fisher Scientific
• Merck KGaA（MilliporeSigma）
• Trilink Biotechnologies（Maravai）
• Integrated DNA Technologies（IDT）
• New England Biolabs
• Jena Bioscience
• Hongene Biotech
• GenScript Biotech
• Arctus Biosciences
• Codex DNA（Twist Bioscience）
• Aldevron（Danaher）
• PNABio Inc.
• CureVac AG
• BioNTech SE
• Moderna Inc.
• Ajinomoto Bio-Pharma Services
• Catalent Inc.
• Recombinant Technology Inc.
• GlycoMimetics
• Abcam plc

結論與建議

Global mRNA Synthesis Raw Materials Market size was valued at USD 2.52 Billion in 2024 and is poised to grow from USD 2.89 Billion in 2025 to USD 8.85 Billion by 2033, growing at a CAGR of 14.82% during the forecast period (2026-2033).

The market for mRNA synthesis raw materials is being propelled by the surging demand for mRNA vaccines and therapeutics, alongside heightened investment in biotechnology research and a broadened clinical pipeline for related products. The transition of mRNA candidates from research to clinical stages demands increased technological advancements in biomanufacturing and a strong emphasis on personalized medicine. Furthermore, the rise in demand for GMP-grade materials suitable for large-scale production is pushing biotechnology firms to seek regulatory-compliant raw materials. This has led to expanded production capacities for essential components, alleviating supply bottlenecks and enhancing manufacturing efficiency. However, challenges such as high production costs, strict regulations, and supply chain limitations may hinder market growth despite the promising potential of next-gen vaccines and therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global mRNA Synthesis Raw Materials market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global mRNA Synthesis Raw Materials Market Segments Analysis

Global mRNA synthesis raw materials market is segmented by raw material type, application, end-user, distribution channel, and region. Based on raw material type, the market is segmented into Nucleoside Triphosphates (NTPs), Modified Nucleosides (m1Ψ, pseudouridine), Cap Analogs (ARCA, CleanCap), Poly-A Tailing Reagents, and Plasmid DNA Templates. Based on application, the market is segmented into vaccine manufacturing, therapeutics, and research. Based on end-user, the market is segmented into mRNA vaccine manufacturers, pharma & biotech companies, and CDMOs. Based on distribution channel, the market is segmented into direct B2B and distributors. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Driver of the Global mRNA Synthesis Raw Materials Market

The increasing demand for mRNA-based drugs and therapies is significantly driving the need for raw materials as biopharmaceutical companies enhance their development pipelines and seek wider applications. This surge in demand for high-quality nucleotides, enzymes, and specialized reagents is prompting manufacturers to transition from concept to clinical trials and ultimately to market release. Consequently, suppliers are encouraged to scale operations and innovate solutions for these essential raw materials. The continuous growth in this sector will attract investment in value chains and foster a supply network that supports expanding supplier capabilities, thereby facilitating new mRNA applications and enhancing market accessibility.

Restraints in the Global mRNA Synthesis Raw Materials Market

The Global mRNA Synthesis Raw Materials market faces significant constraints due to the inherent complexity of its supply chain, which impacts market size and penetration. A limited number of suppliers provide key niche inputs, creating vulnerabilities in availability and stability. The transportation of temperature-sensitive materials further complicates logistics, leading to potential delays and quality issues that encourage conservative inventory practices. This uncertainty in securing essential materials hampers rapid scaling of manufacturing processes, establishing higher barriers for new entrants and innovative formulations. Consequently, buyers tend to favor established, reliable suppliers, resulting in slower adoption of emerging manufacturers and novel products in the market.

Market Trends of the Global mRNA Synthesis Raw Materials Market

The Global mRNA Synthesis Raw Materials market is experiencing a significant trend driven by therapeutic platform diversification. Expanding applications of mRNA technology, particularly in oncology, rare diseases, and regenerative medicine, are generating a heightened demand for an expanded range of high-quality raw materials. Consequently, reagent suppliers are now providing specialized nucleotides, modified cap structures, and unique excipients designed to meet specific therapeutic needs. This evolution is prompting enhanced collaboration between reagent manufacturers and biotechnology firms to establish custom specifications for these materials, underscoring the importance of tailored solutions in meeting the diverse requirements of the mRNA synthesis market.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global mRNA Synthesis Raw Materials Market Size by Raw Material Type & CAGR (2026-2033)

• Market Overview
• Nucleoside Triphosphates (NTPs)
• Modified Nucleosides (m1Ψ, pseudouridine)
• Cap Analogs (ARCA, CleanCap)
• Poly-A Tailing Reagents
• Plasmid DNA Templates

Global mRNA Synthesis Raw Materials Market Size by Application & CAGR (2026-2033)

• Market Overview
• Vaccine Manufacturing
• Therapeutics
• Research

Global mRNA Synthesis Raw Materials Market Size by End-User & CAGR (2026-2033)

• Market Overview
• mRNA Vaccine Manufacturers
• Pharma & Biotech Companies
• CDMOs

Global mRNA Synthesis Raw Materials Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Direct B2B
• Distributors

Global mRNA Synthesis Raw Materials Market Size & CAGR (2026-2033)

• North America (Raw Material Type, Application, End-User, Distribution)
  • US
  • Canada
• Europe (Raw Material Type, Application, End-User, Distribution)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Raw Material Type, Application, End-User, Distribution)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Raw Material Type, Application, End-User, Distribution)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Raw Material Type, Application, End-User, Distribution)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Thermo Fisher Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (MilliporeSigma)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Trilink Biotechnologies (Maravai)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Integrated DNA Technologies (IDT)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• New England Biolabs
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jena Bioscience
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hongene Biotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GenScript Biotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arctus Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Codex DNA (Twist Bioscience)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aldevron (Danaher)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PNABio Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CureVac AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ajinomoto Bio-Pharma Services
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recombinant Technology Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlycoMimetics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abcam plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations